Lesson plan

Zamicastat

Zamicastat ( ; developmental code name BIA-5-1058) is a peripherally selective dopamine β-hydroxylase (DBH) inhibitor which is under development for the treatment of pulmonary arterial hypertension (PAH) and heart failure. It is structurally related to etamicastat and is said to be an improved version of this drug. As of July 2022, zamicastat is in phase 2 clinical trials for PAH and phase 1 clinical trials for heart failure. However, no recent development has been reported for heart failure.

Back to article

Article summary

Zamicastat ( ; developmental code name BIA-5-1058) is a peripherally selective dopamine β-hydroxylase (DBH) inhibitor which is under development for the treatment of pulmonary arterial hypertension (PAH) and heart failure. It is structurally related to etamicastat and is said to be an improved version of this drug. As of July 2022, zamicastat is in phase 2 clinical trials for PAH and phase 1 clinical trials for heart failure. However, no recent development has been reported for heart failure.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.